Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”-Reference-Cited by-同舟云学术

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”

Published:2023-07-07 Issue:10 Volume:64 Page:1715-1718
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Mele Giuseppe¹^ORCID,Di Renzo Nicola²,Cascavilla Nicola³,Carella Angelo Michele³,Guarini Attilio⁴,Mazza Patrizio⁵,Melillo Lorella⁶,Pavone Vincenzo⁷,Tarantini Giuseppe⁸,Curci Paola⁹,Falcone Anna P.²,Germano Candida⁸,Mele Anna⁷,Merchionne Francesca¹,Palazzo Giulia⁵,Palumbo Gaetano⁶,Quinto Angela Maria⁵,Reddiconto Giovanni³,Rossini Bernardo⁴,Spina Alessandro¹,Sgherza Nicola⁹,Specchia Giorgina⁹,Musto Pellegrino⁹,Pastore Domenico¹

Affiliation:

1. Haematology, Ospedale A. Perrino, Brindisi, Italy

2. Haematology, Ospedale V. Fazzi, Lecce, Italy

3. Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy

4. Haematology, Ospedale Giovanni Paolo II, Bari, Italy

5. Haematology, Ospedale G. Moscati, Taranto, Italy

6. Haematology, Ospedali Riuniti, Foggia, Italy

7. Haematology, Ospedale Cardinale Panico, Tricase (Lecce), Italy

8. Haematology, Ospedale Monsignor R. Dimiccoli, Barletta (Bari), Italy

9. Policlinico, University of Bari Medical School, Bari, Italy

Publisher

Informa UK Limited